Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.

Chen, Shiyun; Han, Lu; Guo, Shiyuan; Tan, Zhaoli; Dai, Guanghai

Chen, Shiyun; Han, Lu; Guo, Shiyuan; Tan, Zhaoli; Dai, Guanghai.

Afiliación

Chen S; Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Han L; Department of Oncology, Medical School of Chinese PLA, Beijing, China.
Guo S; Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Tan Z; Department of Oncology, Medical School of Chinese PLA, Beijing, China.
Dai G; Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.

Hum Vaccin Immunother ; 19(2): 2252692, 2023 08 01.

Article en En | MEDLINE | ID: mdl-37675466

Asunto(s)

Neoplasias Pancreáticas; Receptor de Muerte Celular Programada 1; Humanos; Antígeno CA-19-9; Inhibidores de Puntos de Control Inmunológico; Estudios Retrospectivos; Neoplasias Pancreáticas/terapia; Neoplasias Pancreáticas

Palabras clave

CA19-9; PD-1 inhibitors; Pancreatic cancer; hyperprogressive disease; tumor growth rate

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Receptor de Muerte Celular Programada 1 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google